Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Organovo Holdings Inc    ONVO

ORGANOVO HOLDINGS INC (ONVO)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/13/2018 07/16/2018 07/17/2018 07/18/2018 07/19/2018 Date
1.34(c) 1.35(c) 1.34(c) 1.37(c) 1.32(c) Last
546 482 427 277 453 839 336 392 740 935 Volume
-0.74% +0.75% -0.74% +2.24% -3.65% Change
More quotes
Financials (USD)
Sales 2019 6,16 M
EBIT 2019 -34,5 M
Net income 2019 -34,4 M
Finance 2019 22,5 M
Yield 2019 -
Sales 2020 10,4 M
EBIT 2020 -33,3 M
Net income 2020 -35,7 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 20,5x
Capi. / Sales2020 14,4x
Capitalization 149 M
More Financials
Company
Organovo Holdings, Inc. is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications.It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be... 
Sector
Biotechnology & Medical Research
Calendar
07/26 | 06:00pmShareholder meeting
More about the company
Surperformance© ratings of Organovo Holdings Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ORGANOVO HOLDINGS INC
07/19Organovo Announces Release Date for Fiscal First-Quarter 2019 Financial Resul..
GL
05/31ORGANOVO : Fiscal 4Q Earnings Snapshot
AQ
05/31ORGANOVO HOLDINGS, INC. : Results of Operations and Financial Condition, Financi..
AQ
05/31ORGANOVO : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
05/31ORGANOVO : Reports Fiscal Fourth-Quarter and Full-Year 2018 Results; Company Ann..
AQ
05/14Organovo Announces Release Date for Fiscal Fourth-Quarter 2018 Financial Resu..
GL
05/11ORGANOVO : to Present New Preclinical Data for Its Liver Therapeutic Tissue IND-..
AQ
05/10Organovo to Present New Preclinical Data for Its Liver Therapeutic Tissue IND..
GL
05/04ORGANOVO : and Samsara Sciences Partner with New Manufacturing USA Institute
AQ
05/03Organovo and Samsara Sciences Partner with New Manufacturing USA Institute
GL
More news
Sector news : Biotechnology & Medical Research - NEC
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/19Organovo Announces Release Date for Fiscal First-Quarter 2019 Financial Resul.. 
07/05Want automatic email alerts for $KONA $KT $ONVO $MDCO $SUG? Subscribe to Mark.. 
07/05Paul Gallant out on recent $FB headlines, analyzing scope and significance of.. 
07/03$ONVO  
07/03Contrasting Organovo $ONVO and Halozyme Therapeutics $HALO  
More tweets
Qtime:468
News from SeekingAlpha
07/03Organovo Shareholders Could Have Even More Downside Ahead 
06/11HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (06/11/2018) 
06/08ORGANOVO HOLDINGS : A Small Biotech At A Great Valuation 
06/01Midday Gainers / Losers (06/01/2018) 
06/01HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (06/01/2018) 
Chart ORGANOVO HOLDINGS INC
Duration : Period :
Organovo Holdings Inc Technical Analysis Chart | ONVO | US68620A1043 | 4-Traders
Technical analysis trends ORGANOVO HOLDINGS INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 2,67 $
Spread / Average Target 95%
EPS Revisions
Managers
NameTitle
Taylor J. Crouch President, Chief Executive Officer & Director
Kirk D. Malloy Chairman
Craig S. Kussman Chief Financial Officer
Sharon Collins Presnell Chief Scientific Officer
James T. Glover Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ORGANOVO HOLDINGS INC-1.49%149
CELLTRION, INC.--.--%32 830
IQVIA HOLDINGS INC12.03%22 488
LONZA GROUP9.31%21 400
INCYTE CORPORATION-25.70%14 887
SEATTLE GENETICS, INC.27.16%10 750